DOCSLIB.ORG

United States Patent [191 4,617,293

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent [191 4,617,293 United States Patent [191 [11] Patent Number: 4,617,293 Wahlig et al. [45] Date of Patent: Oct. 14, 1986 [54] FLAVONOID PI-IOSPHATE SALTS OF [52] us. c1. ...................................... .. 514/41; 514/37; AMINOGLYCOSIDE ANTIBIOTICS 514/39; 536/8; 536/13.2; 536/13.3; 536/13.8; 536/14; 536/l6.8 [75] Inventors: Helmut Wahlig, Darmstadt; Elvira [58] Field of Search .............. .. 536/8, 13.2, 13.3, 13.8, Dingeldein, Dreieich; Richard 536/16.6, 14; 514/37, 41, 39 Kirchlechner, Rott a. Inn; Dieter ()rth, Darmstadt; Werner Rogalski, [56] References Cited Alsbach, all of Fed. Rep. of U.S. PATENT DOCUMENTS Germany 2,962,495 11/1960 Ferno et al. .......................... .. 536/8 [73] Assignee: Merck Patent Gesellschaft mit 3,091,572 5/1963 Luedemann et al. .'. .......... .. 536/l3.6 beschraenkter Haftung, Darmstadt, Fed. Rep. of Germany OTHER PUBLICATIONS Rinehart, Jr. and Suami, Ed., Aminocyclitol Antibiot [21] Appl.N0.: 613,131 ics, ACS Symposium Series 125, Washington, D.C., [22] Filed: May 23,1984 1980. Primary Examiner-Johnnie R. Brown Related US. Application Data Assistant Examiner-Elli Peselev [63] Continuation-impart of Ser. No. 377,779, May 13, Attorney, Agent, or Firm—Millen & White 1982, abandoned. [57] ABSTRACT [30] Foreign Application Priority Data Flavonoid phosphates of aminoglycoside antibiotics are useful sparingly soluble salts, e.g., for achieving a depot May 13, 1981 [DE] Fed. Rep. of Germany ..... .. 3118856 effect. Feb. 25, 1982 [DE] Fed. Rep. of Germany ..... .. 3206725 [51] Int. 01.4 ..................... .. A61K 31/71; 00711 15/22 12 Claims, N0 Drawings 4,617,293 1 2 ?avane system, but can also be in the 4-, 8-, 2’-, 5'- or FLAVONOID PHOSPHATE SALTS OF 6’-position. The 3’- and S-positions are preferred. AMINOGLYCOSIDE ANTIBIOTICS One or more of the hydroxy groups can be esteri?ed with phosphoric acid. This, for example, the 3'- and This application is a continuation-in-part of US. Ser. 5 5-monophosphates and the 3',5-diphosphate of hesperi No. 377,779, ?led on May 13, 1982, now abandoned, din can be used as salt-forming component. In all of the May 24, 1984 and whose disclosure is incorporated by following text, the expression “hesperidin-phosphoric reference herein. acid” relates to the 3',5-diphosphate and the expression "hesperidin-phosphate(s)” relates to the salts derived BACKGROUND OF THE INVENTION therefrom. The present invention relates to new sparingly solu In addition to the phosphorylated and free OH ble salts of aminoglycoside antibiotics. groups, the ?avonoid phosphoric acids can also carry Aminoglycoside antibiotics such as gentamycin or other substituents, for example etheri?ed OH groups, tobramycin are usually employed in the form of their such as alkoxy groups of, preferably, 1-4 C atoms, sulfates, which are readily soluble in water. The antibi above all methoxy groups (as a rule not more than otics are rapidly released from these salts and distribute three, preferably one, and preferably in the 4’-position, themselves around the body. In some cases, this prop but also in the 3-, 3'-, 5-, 6- and/or 7-position), and, in erty is a disadvantage, in particular if a locally limited particular, glycosidated OH groups. These can be infection is to be combatted, for example an infected glycosidated with mono-, di-, tri- or tetra-saccharides. bone. In these cases, more sparingly soluble salts, from Preferred glycoside components are monosaccharides, which the antibiotic is released more slowly and which e.g., D-glucose, and also D-galactose, D-glucuronic therefore can display a certain depot action, are desir acid, D-galacturonic acid, D-xylose, D-apiose, L-rham able. nose and L-arabinose, and disaccharides, e.g., rham Some sparingly soluble salts of aminoglycoside anti nosylglucoses, particularly preferably rutinose and neo biotics are known. Thus, for example, U.S. Pat. No. 25 hesperidose, and also, for example, rungiose, robinobi 3,091,572 mentions various sparingly soluble salts of ose, sophorose, gentiobiose, apiobiose, vicianose, sam gentamycin (for example, salts of fatty acids containing bubiose, primverose or latyrose. Glycosidated OH groups are preferably in the 7- and/or 3-position; at 8 or more C atoms, e.g., lauric acid, stearic acid, palmi tic acid or oleic acid; aralkanoic acids, e.g., phenyl most 2, and preferably one, glycosidated OH group is as a rule present in the molecule of the ?avonoid phos- ' butyric acid; arylcarboxylic acids, e.g., naphthalene-l phoric acid. Examples of other possible substituents (as carboxylic acid; and sulfuric and sulfonic acids, e.g., a rule not more than 3, preferably only one) include laurylsulfuric acid and dodecylbenzenesulfonic acid). alkyl of, for example, 1-4 C atoms, preferably methyl, It has been found that these salts display certain dis halogen, preferably F or Cl, and hydroxyalkoxy of, for advantages when used For example, they have a waxy, 35 example, l-4 C atoms, preferably 2-hydroxyethoxy. clearly hydrophobic nature which impedes their galeni Examples of speci?c ?avonoid phosphates include cal processing. phosphoric acid half-esters of hydroxy?avanes, e.g., SUMMARY OF THE INVENTION 6-hydroxy-4’-methoxy?avane, 6-hydroxy-3,4'-dime thoxy?avane, 6-hydroxy-4'-methoxy-3-methyl?avane, Accordingly, it is an object of this invention to pro 40 catechol ((+)-3,3’,4’,5,7-pentahydroxy?avane) and vide new salts of antibiotics which are sparingly soluble leucocianidol (3,3',4,4’,5,7-hexahydroxy?avane) and and which do not have the adverse properties of the glycosides thereof, e.g., 2,3,3',4,4',5,7-heptahydroxyfla known antibiotic salts or display them only to a minor vane glucoside; hydroxy?avanones, e.g., liquiritigenin degree. (4‘,7-dihydroxy?avanone), pinocembrin (dihydrochry Upon further study of the speci?cation and appended 45 sin, 5,7-dihydroxyflavanone), naringenin (4',5,7-trihy claims, further objects and advantages of this invention droxy?avanone), eriodictyol (3',4',5,7-tetrahydroxy will become apparent to those skilled in the art. flavanone), dihydroquercetin (taxifolin, 3,3',4',5,7-pen These objects have been achieved by this invention tahydroxy?avanone), 6-hydroxy-4'-methoxy?avanone, and the ?nding that a slower release of the antibiotics sacuranetin (4’,5-dihydroxy-7-methoxy-flavanone), can be achieved if the sparingly soluble ?avonoid phos isosacuranetin (5,7-dihydroxy-4'-methoxy-?avanone), phates, in particular the hesperidin-phosphates, of the hesperetin (3',5,7-trihydroxy-4'-methoxy?avanone) and aminoglycoside antibiotics are used instead of the men silibinin (2-[trans-2-(4-hydroxy-3-methoxyphenyl)-3 tioned sulfates or other readily soluble salts. hydroxymethyl-1,4-benzodioxan-6-yl]-3,5,7-trihydrox This invention accordingly relates to the ?avonoid ychroman-4-one) and glycosides thereof, e.g., pinocem phosphates, in particular the hesperidin-phosphates, of 55 brin 7-rutinoside, sarothanoside (pinocembrin 7-neohes aminoglycoside antibiotics. peridoside), salipurposide (naringenin 5glucoside), pru nin (naringenin 7-glucoside), narirutin (naringenin 7 DETAILED DISCUSSION rutinoside), naringin (naringenin 7-neohesperiodoside), Suitable anionic components of the salts of this inven eriodictin (eriodictyol 7-rhamnoside), eriocitrin (erio tion include phosphoric acid half-esters of hydroxy 60 dictyol 7-rutinoside), eriodictyol 7-neohesperidoside, ?avonoids, for example of hydroxy-?avanes, -?avenes, didymin (isosacuranetin 7-rutinoside), poncirin -?avanones, -flavones or -?avylium salts. The flavanone (isosacuranetin 7-neohesperidoside), persicoside (hes and ?avone derivatives are preferred. peritin glucoside), hesperidin (hesperetin 7-rutinoside), The hydroxyflavonoids can contain one or more, for and neohesperidin (hesperetin 7-neohesperidoside); hy example 1, 2, 3, 4, 5, 6 or 7, preferably 1, 2, 3 or 4, 65 droxy?avones, e.g., chrysin (5,7-dihydroxy?avone), hydroxy groups, which are preferably of a phenolic primetin (5,8-dihydroxyflavone), galangin (3,5,7-trihy nature, but can also be of the alcoholic type. They are as droxy?avone), baicalein (5,6,7-trihydroxy?avone), a rule in the 3-, 5-, 6-, 7-, 3’- and/or 4’-position of the apigenin (4',5,7-trihydroxyflavone), datiscetin (2',3,5,7 4,617,293 3 4 tetrahydroxy?avone), loto?avin (2’,4',5,7-tetrahydrox polybasic acids, it is furthermore possible for acid, neu yflavone), caempferol (3,4’,5,7-tetrahydroxyflavone), tral and/or basic salts to be formed. All these possible ?setin (3,3',4’,7-tetrahydroxyflavone), luteolin (3',4’,5,7~ salts and their mixtures with one another are included in tetrahydroxy?avone), scutellarein (4',5,6,7tetrahydrox the term “a flavonoid phosphate of an aminoglycoside yflavone), morin (2',4,4',5,7-pentahydroxy?avone), ro antibiotic” and analogous terms used herein. binetin (3,3',4’5‘,7-pentahydroxyflavone), quercetin The neutral salts and mixtures containing these are (3,3',4',5,7-pentahydroxy?avone), tectochrysin (5 preferred. In the case of the gentamycin hesperidin hydroxy-7-methoxyflavone), genkwanin (4',5-dihy phosphates, for example, the salt (mixture) of 2 moles of droxy-7-methoxyflavone), acacetin (5,7-dihydroxy-4’ gentamycin and 5 moles of hesperidin-phosphoric acid methoxyflavone), diosmetin (3 ’,5,7-trihydroxy-4' is particularly preferred. (“Neutral” in this context methoxy?avone), chrysoeriol (4’,5,7-trihydroxy-3' means that there is one basic amino group per phos methoxyflavone), rhamnetin (3,3',4’,5-tetrahydroxy-7 phoric acid radical). methoxy?avone), isorhamnetin (3,4',5,7-tetrahydroxy The invention also relates to a process for the prepa
Load more

Recommended publications
  • Determination of the Major Flavonoid from Qina (Eucalyptus Globules L.) Using Shift Reagent, UV and IR Spectrophotometry
    Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam B.Sc. Science and Education, El-Zeim Alazhari University( 2003) Postgraduate Diploma in Applied Chemistry, Gezira University( 2009) A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Department of Applied Chemistry and Chemical Technology Faculty of Engineering and Technology Supervisor: Prof.Mohamed Abdel Karim Mohamed Co-supervisor:Dr. Mohamed Osman Babiker October -2012 ~1~ Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam Examination Committee: Name Position Signature Prof.Mohamed Abdel Karim Mohame Chairperson ................. Dr. Abo Bakr Khidir Ziada Intarnal Examiner …………. Dr. Abd Elsalam Abdalla Dafa Alla Extarnal Examiner …….. Date OF Examination: 6\10\2012 ~2~ Dedication This work is dedicated to My father who Deserved all respect, my mother For her care and passion, my husband for his help and support, my family and Friends. ~3~ Acknowledgements I thank Allah, Almighty for help. I wish to express my deep gratitude to my supervisor Prof. Mohamed Abdel Karim Mohamed for supervision and advice. I am grateful to all those who helped me to finish this thesis. My thanks are also extended to my colleagues for kind support. ~4~ Abstract Qina bark (Eucalyptus globules.L) is used in ethnomedicine as anti- inflammatory and antimalarial remedy.This study was aimed to extract and determine the physiochemical properties of the major flavonoid of quina bark. The plant material was collected from northern Kordofan and extracted with ethanol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • EP1776161B1.Pdf
    (19) TZZ____T (11) EP 1 776 161 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 5/02 (2006.01) A61Q 7/00 (2006.01) 26.10.2016 Bulletin 2016/43 A61Q 19/00 (2006.01) A61K 8/36 (2006.01) A61K 8/362 (2006.01) A61K 8/37 (2006.01) (2006.01) (2006.01) (21) Application number: 05718804.7 A61K 8/39 A61Q 1/02 A61Q 5/06 (2006.01) A61K 8/64 (2006.01) A61Q 5/12 (2006.01) A61Q 11/00 (2006.01) (22) Date of filing: 25.04.2005 A61K 8/81 (2006.01) A61Q 19/06 (2006.01) A61Q 19/08 (2006.01) A61K 8/97 (2006.01) A61K 8/42 (2006.01) A61K 8/49 (2006.01) A61Q 5/00 (2006.01) A61K 8/73 (2006.01) (86) International application number: PCT/IB2005/051344 (87) International publication number: WO 2005/102266 (03.11.2005 Gazette 2005/44) (54) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER KOSMETISCHE ODER DERMOPHARMAZEUTISCHE ZUSAMMENSETZUNG MIT MINDESTENS EINEM UDP-GLUCURONOSYL-TRANSFERASE (UGT) ENZYM-INDUKTOR COMPOSITION COSMETIQUE OU DERMOPHARMACEUTIQUE COMPRENANT AU MOINS UN INDUCTEUR D’ENZYMES UDP-GLUCURONOSYLTRANSFERASES (UGT) (84) Designated Contracting States: • PATENT ABSTRACTS OF JAPAN vol. 2000, no. DE ES FR GB IT 14, 5 March 2001 (2001-03-05) & JP 2000 319154 A(NIPPON MENAADEKESHOHIN KK; ICHIMARU (30) Priority: 26.04.2004 FR 0404408 PHARCOS CO LTD), 21 November 2000 (2000-11-21) (43) Date of publication of application: • DATABASE WPI Derwent Publications Ltd., 25.04.2007 Bulletin 2007/17 London, GB; AN 2001-481491 XP002309671 CHEOUNG J H ET AL.: "Chrysin 7-o-crotonate, its (73) Proprietor: Sederma S.A.S.
    [Show full text]
  • 1 Revealing SARS-Cov-2 Functional Druggability Through Multi-Target
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 May 2020 doi:10.20944/preprints202005.0199.v1 Revealing SARS-CoV-2 Functional Druggability Through Multi-Target Cadd Screening of Repurposable Drugs Yash Gupta1,2, Dawid Maciorowski1,3, Raman Mathur1, Catherine M Pearce1, David J. IIc1,3, Hamza Husein1,3, Ajay Bharti4, Daniel P. Becker3, Brijesh Rathi2,5, Steven B Bradfute6, Ravi Durvasula1,2, Prakasha Kempaiah1,2* 1 Loyola University Chicago Stritch School of Medicine, Chicago, IL, 60153, USA; 2 Department of Medicine, Loyola University Medical Center, Chicago, IL, 60153, USA; 3 Loyola University Chicago, Chicago, IL, USA; 4 Division of Infectious Diseases, Department of Medicine, University of California, San Diego, CA, 92093, USA, 5 Laboratory for Translational Chemistry and Drug Discovery, Hansraj College, University of Delhi, India; 6 Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Number of Tables: 10; Number of Figures: 16 ABSTRACT: The emergence of SARS/MERS drug resistant COVID-19 with high transmission and mortality has recently been declared a deadly pandemic causing economic chaos and significant health problems. Like all coronaviruses, SARS-CoV-2 is a large virus that has many druggable components within its proteome. In this study, we focused on repurposing approved and investigational drugs by identifying potential drugs that are predicted to effectively inhibit critical enzymes within SARS-CoV-2. We shortlisted seven target proteins with enzymatic activities known to be essential at different stages of the virus life cycle. For virtual screening, the energy minimization of a crystal structure or modeled protein was carried out using Protein Preparation Wizard (Schrödinger LLC, 2020-1).
    [Show full text]
  • Flavonoid Compounds Benzquercin (R!NN)
    Gilenya; Norw. : Gilenya; Spain: Gilenya; Swed.: Gilenya; reintroduction of fingolimod if treatment has been stopped Oxerutins (BAN) for more than 2 weeks, and the precautions for re�initiating Switz.: Gilenya; Turk.: Gilenya; UK: Gilenya; USA: Gilenya. treatment outlined above should be followed. Hidroxileti!rut6sidos; Hydroxyethyir�tosides; Oxerutlnas: Fingolimod may increase the risk of developing 0Kcepynmot infections due to the reduction in peripheral lymphocyte Flavonoid Compounds Description. Oxerutins consist of a mixture of 5 different count (see Uses and Administration, p. 2504.3), and 0-(P-hydroxyethyl)rutosides, not less than 45% of which is mo f!avonoides; 8iofiavonoids; Flavonoides: Vitarnin treatment should not be started in patients without a recent P troxerutin (trihydroxyethylrutoside, below), but which also Substances; Vitamlnas full blood count taken within the previous 6 months. P; <DnqBOHOMj:jol. includes monohydroxyethylrutoside, dihydroxyethylruto­ Fingolimod should not be started in patients with active side, and tetrahydroxyethylrutoside. acute or chronic infections. Patients should be monitored Benzquercin (r!NN) for signs and symptoms of infection during treatment and Quercetin for 2 months after treatment has stopped. Stopping Benzqueccina; Benzquercine; Benzquercinum; 6et!3KB€PLi�H. fingolimod should be considered if a patient develops a 3,3',4';5,7-Pentakis(benzyloxy) flavone. Quercetina; Keep:.;erv.H: 3,3',4',5,7-Pentahydroxyftavone. serious infection during treatment, and then the risks versus C,oKNJ0,=752.9 2-(3,4-Dihydroxyphenyl)-3,5,7-trihy droxy�4H- 1 -benzopyran- benefits reassessed before treatment is resumed. 4--one, Patients without a history of chickenpox or who have not C4$ - 13157-90-9. received varicella Mzoster vaccination should be tested for UN/! - 499L710 905.
    [Show full text]
  • Daflon® 500 Mg Tablets
    Vasoprotectives Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases Final Report LBI-HTAProject Report No./Projektbericht Nr.: 79 ISSN: 1992-0488 ISSN-online: 1992-0496 Vasoprotectives Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases Final Report Vienna, December 2014 Project Team/Projektteam Project Management/Projektleitung: Dr. rer. soc.oec. Ingrid Zechmeister-Koss Authors/AutorInnen: Dipl. Ges-oec. Stefan Fischer Dr. rer. soc.oec. Ingrid Zechmeister-Koss Additional contribution/Projektbeteiligung: Dr. Anna Glechner (Danube University Krems, performedmeta-analysis) Systematic Literature Search/Systematische Literatursuche: Tarquin Mittermayr, BA Hand Search/Handsuche: Stefan Fischer External Review/Externe Begutachtung: Priv.-Doz. Dr. med. univ. Thomas Gary (Klinische Abteilung für Angiologie, Meduni Graz) Dipl.-Ing. Erich Kvas (Hermesoft, Graz) Internal Review/Interne Begutachtung: Priv.-Doz. Dr. phil. Claudia Wild Correspondence/Korrespondenz: Stefan Fischer: [email protected] This report should be referenced as follows/Dieser Bericht soll folgendermaßen zitiert werden: Fischer S, Zechmeister-Koss I: Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases. LBI-HTA Project Report No.: 79, 2014, Vienna: Ludwig Boltzmann Institute for Health Technology Assessment. Conflict of Interest/Interessenskonflikt All authors declare no conflict of interest in sense
    [Show full text]
  • Ep 2858641 B1
    (19) TZZ __T (11) EP 2 858 641 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/352 (2006.01) A61K 31/35 (2006.01) 06.09.2017 Bulletin 2017/36 A61P 17/00 (2006.01) A61Q 1/06 (2006.01) A61Q 1/14 (2006.01) A61K 8/49 (2006.01) (2006.01) (2006.01) (21) Application number: 13800034.4 A61K 8/60 A61Q 17/04 A61Q 19/08 (2006.01) A61K 8/86 (2006.01) A61Q 19/10 (2006.01) A61K 8/97 (2017.01) (22) Date of filing: 06.06.2013 A61K 8/99 (2017.01) A61Q 19/00 (2006.01) (86) International application number: PCT/US2013/044464 (87) International publication number: WO 2013/184884 (12.12.2013 Gazette 2013/50) (54) IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION VERBESSERTES VERFAHREN FÜR PFLANZEN- UND/ODER ALGENEXTRAKTION PROCÉDÉS AMÉLIORÉS POUR L’EXTRACTION DE VÉGÉTAUX ET/OU D’ALGUES (84) Designated Contracting States: • JUDD, Christopher AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Riverhead, NY 11901 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • RICHTER, Nicole Jeannine PL PT RO RS SE SI SK SM TR Port Jefferson, NY 11777 (US) (30) Priority: 06.06.2012 US 201261656221 P (74) Representative: Herzog, Fiesser & Partner Patentanwälte PartG mbB (43) Date of publication of application: Isartorplatz 1 15.04.2015 Bulletin 2015/16 80331 München (DE) (73) Proprietors: (56) References cited: • BASF Corporation WO-A1-2011/140655 KR-B1- 100 741 644 Florham Park, NJ 07932 (US) US-A1- 2006 078 633 US-A1- 2006 099 690 • BASF Beauty Care Solutions France SAS US-A1- 2011 190 175 69007 Lyon (FR) • MINUTH, T.
    [Show full text]
  • Supplementary Materials: Comprehensive
    Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S1 of S14 Supplementary Materials: Comprehensive Ingredients Qualitative Profiling of Chinese Herbal Formula Wu-Zhu-Yu Decoction Based on Mass Defect and Fragment Filtering Approach Using High Resolution Mass Spectrometry Huarong Xu, Huibin Niu, Bosai He, Chang Cui, Qing Li and Kaishun Bi Figure S1. Fragmentation pattern of goshuyuamide and hydroxygoshuyuamide. (A) Representative fragments of goshuyuamide and hydroxygoshuyuamide; (B) product ion MS/MS spectrum of goshuyuamide; (C) product ion MS/MS spectrum of hydroxygoshuyuamide. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S2 of S14 Figure S2. (A) Fragmentation pathways and product ion MS/MS spectrums of (A) PPD type ginsenoside Rd and (B) PPT type ginsenoside Re. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S3 of S14 Figure S3. Fragmentation pathways and product ion MS/MS spectrums of rutin in (A) positive and (B) negative ion mode. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S4 of S14 Figure S4. Fragmentation pathways and product ion MS/MS spectrums of chlorogenic acid in (A) positive and (B) negative ion mode. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S5 of S14 Table S1. Characterization of the ingredients in Wu-Zhu-Yu decoction by LC high resolution MS. Ion Theoretical Measured Error/ No. Compound Formula tR/min Product Ions (m/z, Da) Adduction m/z (Da) m/z (Da) ppm Evodiamine and its analogous alkaloids 134.0599, 161.0711, 176.0707, 148.0394, 146.0597, 120.0446, 160.0636, 1 Dihydroxyevodiamine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0170574 A1 Bleckmann Et Al
    US 2004O170574A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0170574 A1 Bleckmann et al. (43) Pub. Date: Sep. 2, 2004 (54) AUTOMATICALLY FOAMING OR (57) ABSTRACT FOAM-TYPE PREPARATIONS COMPRISING Self-foaming and/or foam-like cosmetic or dermatological NORGANIC GEL FORMERS preparations which comprise I. an emulsifier System which consists of (76) Inventors: Andreas Bleckmann, Ahrensburg (DE); A. at least one emulsifier Achosen from the group of Rainer Kropke, Schenefeld (DE); wholly neutralized, partially neutralized or unneu Heidi Riedel, Hamburg (DE) tralized branched and/or unbranched, Saturated and/or unsaturated fatty acids having a chain Correspondence Address: length of from 10 to 40 carbon atoms, GREENBLUM & BERNSTEIN, P.L.C. B. at least one emulsifier B chosen from the group of 1950 ROLAND CLARKE PLACE polyethoxylated fatty acid esters having a chain RESTON, VA 20191 (US) length of from 10 to 40 carbon atoms and a degree of ethoxylation of from 5 to 100 and (21) Appl. No.: 10/469,695 C. at least one coemulsifier C chosen from the group of Saturated and/or unsaturated, branched and/or unbranched fatty alcohols having a chain length of (22) PCT Filed: Mar. 14, 2002 from 10 to 40 carbon atoms, II. up to 30% by weight-based on the total weight of (86) PCT No.: PCT/EPO2/O2851 the preparation-of a lipid phase, III. 1 to 90% by volume, based on the total volume of (30) Foreign Application Priority Data the preparation, of at least one gas chosen from the group consisting of air, OXygen, nitrogen, helium, Mar.
    [Show full text]
  • Target and Suspect Screening of Contaminants of Emerging Concern in Raw Water and Drinking Water from Europe and Asia
    Water Research 198 (2021) 117099 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres What’s in the water? –Target and suspect screening of contaminants of emerging concern in raw water and drinking water from Europe and Asia ∗ Rikard Tröger a, , Hanwei Ren b, Daqiang Yin b, Cristina Postigo c, Phuoc Dan Nguyen d, Christine Baduel e, Oksana Golovko a,f, Frederic Been g, Hanna Joerss h, Maria Rosa Boleda i, Stefano Polesello j, Marco Roncoroni k, Sachi Taniyasu l, Frank Menger a, Lutz Ahrens a, Foon Yin Lai a, Karin Wiberg a a Department of Aquatic Sciences and Assessment, Swedish University of Agricultural Sciences (SLU), Box 7050, SE-750 07 Uppsala, Sweden b Key Laboratory of Yangtze River Water Environment, Ministry of Education, College of Environmental Science and Engineering, Tongji University, Shanghai 20 0 092, China c Water, Environmental, and Food Chemistry Unit (ENFOCHEM), Department of Environmental Chemistry, Institute of Environmental Assessment and Water Research (IDAEA-CSIC), Carrer Jordi Girona 18-26, Barcelona, 08034, Spain d Centre Asiatique de Recherche sur l’Eau, Ho Chi Minh City University of Technology, 268 Ly Thuong Kiet, District 10; Vietnam National University of Ho Chi Minh City, Linh Trung Ward, Thu Duc District, Ho Chi Minh City, Vietnam e Université Grenoble Alpes, IRD, CNRS, Grenoble INP, IGE, 38 050 Grenoble, France f University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture
    [Show full text]